India’s National Stock Exchange has received more than $10 billion in investor bids for its $2.3 billion initial public offering, underscoring the strength of demand for exposure to the country’s rapidly expanding retail investment market even as the exchange commands a valuation well above major U.S. peers.

Investors bid for 505.81 million NSE shares on Monday, 5.7 times the 88.64 million shares on offer, according to the IPO data. Demand has been particularly strong among institutional and high-net-worth investors, highlighting the appetite for one of India’s most closely watched listings.

The exchange had already raised 67.5 billion rupees, or about $704 million, from anchor investors last week. The group included the Monetary Authority of Singapore, the Abu Dhabi Investment Authority and Life Insurance Corporation of India.

The offering is India’s largest IPO so far this year and the country’s second-largest ever, behind Hyundai Motor India’s $3.3 billion listing in 2024. The NSE’s public-market debut has also been unusually long in the making, with preparations for a listing stretching back to 2016.

The scale of demand is notable because investors are being asked to pay a substantial premium for the exchange. NSE is valued at about 42.9 times earnings based on the upper end of its IPO price band and earnings per share for the year ended March 2026, according to Yes Securities.

That compares with price-to-earnings ratios of less than 24 times for U.S. stock-exchange companies. Nasdaq trades at about 23.6 times earnings, while Intercontinental Exchange trades at 21.9 times, according to LSEG data. The valuation gap means investors are effectively paying more for NSE’s exposure to India’s capital-market expansion than they are for established U.S. exchange operators.

The rationale for that premium rests largely on NSE’s dominant position and the potential growth of India’s investor base.

NSE controls about 93% of India’s cash equity market and almost 100% of equity futures trading, alongside roughly 75% of equity options trading, according to its IPO filing. India itself has become one of the world’s 10 largest equity markets, with total market capitalization of around 492 trillion rupees, or $5.1 trillion.

That market is also becoming increasingly important to Indian households.

India’s latest Economic Survey said equity investments, previously a relatively small component of household balance sheets, had become a “significant component of financial wealth.” The share of equities and mutual funds in annual household financial savings rose to 15.2% in the financial year ended March 2025, from just 2% in the financial year ended March 2012.

For NSE, that shift creates a potentially powerful structural tailwind. More households participating in equities can translate into higher trading activity, greater derivatives participation and a broader base of investors using the exchange’s infrastructure.

The exchange’s business model adds another attraction. Indian brokerage Geojit Financial Services described NSE as having an “asset-light business model” that supports consistently high margins and cash generation. The brokerage also pointed to rising capital-market participation and what it called increasing “financialization” as providing a long-term growth opportunity.

The key question for investors is whether those growth prospects justify paying almost twice the earnings multiple of some major U.S. exchange operators.

Exchange businesses generally benefit from scale because additional trading volumes can generate revenue without requiring a proportional increase in physical infrastructure. That characteristic can produce strong cash generation when participation and market activity expand.

NSE’s dominance in derivatives gives it another source of revenue and market activity. Equity options have become essential to India’s retail trading boom, although the rapid growth of derivatives also creates regulatory and sustainability questions around retail participation.

The exchange is therefore more than a conventional stock-market infrastructure company. Its valuation is also a bet on continued growth in India’s household participation in financial markets.

There are signs that the potential investor base remains far from saturated. Sundararaman Ramamurthy, managing director of NSE rival Bombay Stock Exchange, said earlier this year that 35 million investors had registered on his platform in 2025 and that a “significant amount of population” had yet to enter the capital markets.

That expansion could support NSE even if foreign investors remain volatile. Ramamurthy has argued that the growing participation of domestic investors helped shield Indian markets from a sharper decline during periods when foreign investors were selling heavily.

The gap between domestic and foreign capital has become an issue for India’s equity market. A larger domestic investor base can provide a more stable source of liquidity and reduce the market’s dependence on global portfolio flows, although it does not eliminate exposure to global risk-off episodes.

For the NSE IPO, the immediate demand is clear. The bigger test will come after the listing, when investors will have to justify the premium valuation through earnings growth and continued expansion of trading activity.

The 5.7-times subscription level suggests that investors are willing to pay for NSE’s market dominance and India’s financialization story. But the comparison with Nasdaq and Intercontinental Exchange shows how much optimism is already embedded in the price.

Thus, investors are not simply buying an exchange. They are paying a premium for a dominant financial infrastructure business at a time when more Indian households are shifting their savings toward equities and other market-based investments. Whether that structural growth can sustain the valuation will become clearer once the company begins trading publicly.

Iambic Therapeutics, a drug developer backed by Nvidia and Qatar’s sovereign wealth fund, has filed for a U.S. initial public offering, adding another biotechnology company to an increasingly active fall pipeline and highlighting the sector’s relative resilience as other parts of the IPO market face rising borrowing costs and geopolitical uncertainty.

The San Diego-based company filed on Monday after two other drug developers, Retension Pharmaceuticals and TRex Bio, submitted IPO paperwork on Friday. ADARx Pharmaceuticals also began its roadshow on Monday, adding to a cluster of biotech listings and planned offerings.

The activity stands out against a more difficult backdrop for new stock offerings. The fall IPO market has faced uncertainty linked to the Iran war, higher bond yields, interest-rate increases, and concerns about how artificial intelligence could disrupt established industries.

Biotech has been less exposed to those pressures, according to IPO analysts, helped in part by continued acquisition activity from large pharmaceutical companies seeking new drugs and promising clinical programs.

“All five of the year’s best-performing IPOs ($50 million deal size and above) are biotechs. Much of that is being driven by drug advancement and M&A,” said Matt Kennedy, senior strategist at Renaissance Capital, which tracks IPOs and manages IPO-focused funds.

Iambic’s offering adds another dimension to the biotech boom because the company is built around the use of artificial intelligence in drug discovery.

Founded in 2019 as Entos, Iambic is developing drug candidates for solid tumors using an AI platform designed to accelerate the discovery of small-molecule therapies. Its most advanced candidate, IAM1363, is being tested in an early-stage clinical trial for solid tumors including breast cancer. The program remains at an early stage, meaning investors will ultimately have to assess the company’s value against the substantial clinical and regulatory risks associated with drug development.

The IPO filing comes on the same day that Iambic announced a multi-year collaboration with AbbVie to accelerate AI-driven discovery of small-molecule medicines.

The agreement expands a partnership network that already includes Takeda, Lundbeck, Revolution Medicines, Jazz Pharmaceuticals and Bayer. The breadth of those relationships provides Iambic with commercial validation for its drug-discovery platform, although partnerships do not guarantee that experimental medicines will successfully reach the market.

Iambic has raised about $461.8 million from technology and healthcare investors since its founding. Its backers include Nvidia and Qatar Investment Authority, alongside Catalio, Nexus Ventures and Coatue Management.

Nvidia’s involvement is notable because the chipmaker has become one of the central financial and technological beneficiaries of the AI boom. Its investment in Iambic extends that exposure beyond computing infrastructure into an industry where AI is being used to shorten parts of the drug-development process.

For investors, that creates a potentially attractive but difficult proposition. AI can help pharmaceutical researchers process biological data, identify potential compounds and improve parts of the drug-discovery workflow, but the technology does not remove the lengthy clinical testing and regulatory process that determines whether a drug can become commercially viable.

Iambic’s most advanced program therefore remains the critical factor for public-market investors. A successful clinical development path could give the company significant value, while disappointing results could quickly undermine the investment case.

The timing of the IPO also matters. Biotechnology companies have historically been sensitive to financing conditions because many developers operate for years before generating meaningful product revenue. Higher interest rates can therefore increase the cost of capital and make speculative growth companies less attractive.

Yet the current biotech IPO pipeline suggests investors remain willing to fund companies with promising clinical programs, particularly where there is a credible path to acquisition by larger pharmaceutical companies. That acquisition backdrop has become more relevant for the sector. Large drugmakers face pressure to replenish pipelines as existing products mature, creating demand for smaller biotechnology companies with promising therapies and technology platforms.

Iambic is attempting to position itself at the intersection of those trends. Its partnerships give it access to established pharmaceutical companies, while its AI platform offers exposure to a technology theme that has attracted enormous investment across the broader economy.

The company’s decision to pursue a public listing also comes after substantial private-market funding. The roughly $462 million it has raised since inception gives Iambic a significant financial base, but the IPO will provide additional capital to advance its clinical pipeline and expand its drug-discovery operations.

Iambic plans to list on the Nasdaq under the ticker “IAM.” J.P. Morgan, Jefferies, BofA Securities and Citigroup are serving as underwriters.

The offering will provide another test of whether investors are willing to assign public-market valuations to AI-enabled biotechnology companies before their leading drug candidates have reached late-stage clinical development.

For the broader IPO market, Iambic’s filing adds to evidence that the reopening of the U.S. listing window is uneven rather than uniform. Companies tied to sectors with identifiable acquisition demand or differentiated technology are finding investors even as higher yields and geopolitical risks make capital markets more selective.

Tesla is laying the groundwork to enter Vietnam, targeting one of Southeast Asia’s fastest-growing electric vehicle markets but also one where a powerful domestic competitor has already established a commanding position.

The US electric vehicle maker registered a local entity, Tesla Motors Vietnam, this month, according to business registration records seen by CNBC. The move creates a corporate structure for potential operations in the country, although Tesla has not disclosed when it might formally launch sales or services.

Vietnam would give Tesla access to a rapidly expanding EV market. But unlike several other Southeast Asian markets where Tesla can compete in a relatively fragmented field, Vietnam already has a dominant local manufacturer, an extensive charging network, and an EV ecosystem built around VinFast.

Vietnam became Southeast Asia’s largest electric car market in 2025 after EV sales more than doubled, with electric vehicles accounting for almost 40% of new-car sales, according to International Energy Agency data released in May.

VinFast, the Nasdaq-listed EV maker backed by Vietnamese conglomerate Vingroup, has captured about 92% of Vietnam’s domestic EV market, according to HSC research. That makes Tesla’s potential entry less a question of creating demand for electric vehicles and more a test of whether it can persuade Vietnamese consumers to switch from a deeply established domestic brand.

VinFast’s Home Advantage

VinFast’s position goes beyond vehicle sales. The company benefits from Vingroup’s broader consumer ecosystem, strong local brand recognition, and an affiliated electric taxi network that has given its vehicles substantial visibility on Vietnamese roads.

It has also built an extensive charging and after-sales network, reducing one of the biggest concerns for EV buyers: whether they can conveniently charge and maintain their vehicle.

“It would be difficult for Tesla to compete with VinFast in Vietnam because VinFast has advantages that go well beyond product availability,” said Koketso Tsoai, senior automobiles analyst at BMI, a unit of Fitch Solutions.

VinFast’s charging infrastructure is a big part of the story. The company has a proprietary network of more than 150,000 charging ports restricted to its EVs, according to Supparoek Sawangwong, ASEAN analyst at Mobility Global. That infrastructure creates a competitive barrier for Tesla. The US company would need to establish its own distribution, service, and charging arrangements in a market where consumers remain sensitive to vehicle prices and ownership costs.

The challenge is different from entering a market where EV infrastructure is still being built. Vietnam already has a functioning EV ecosystem, but much of it is tied to the country’s leading domestic manufacturer.

VinFast has also been expanding rapidly. The company said it sold more than 154,000 vehicles in Vietnam during the first eight months of 2026 and has been the country’s top-selling automaker for 24 consecutive months.

Its share of Vietnam’s passenger-car market rose to an estimated 36% in 2025 from about 22% a year earlier, according to a company filing.

The broader Vingroup ecosystem also provides financial and operational scale. Vingroup generated 221.97 trillion dong ($8.52 billion) in revenue during the first half of 2026, according to its reviewed financial statements.

VinFast’s financial performance, however, shows the cost of pursuing that expansion. The company reported first-quarter revenue of 23.11 trillion dong ($920.7 million), up almost 42% year over year, while its net loss widened 59% to $1.12 billion.

Why Tesla is Interested

The strength of VinFast does not eliminate the attraction of the Vietnamese market. EV sales rose 89% year over year in the second quarter of 2026, according to Peter Richardson, vice president and research director at Counterpoint Research.

That growth gives Tesla a market in which consumer familiarity with electric vehicles is already relatively high.

“Tesla’s biggest advantages in Vietnam are its strong global brand, advanced technology and software, which may appeal to premium EV buyers,” Richardson said.

Vietnam’s broader economic expansion also provides a potential customer base. The economy grew 8% in 2025, while GDP per capita reached $5,066, according to World Bank data.

The immediate opportunity for Tesla is therefore likely to be concentrated among wealthier consumers rather than the mass market. Analysts expect the Model 3 and Model Y to be the most plausible initial products. The Model 3 could compete in the mass-premium sedan segment, while the Model Y would target consumers seeking an electric crossover.

Tesla could also use its Shanghai manufacturing operations to supply Vietnam, potentially giving it a regional production base and greater flexibility over vehicle supply.

But pricing will be critical.

Tesla’s global brand gives it recognition that few EV manufacturers can match, while its software and vehicle technology could differentiate its products. Yet those advantages come with a potential price premium.

For Tesla to move beyond a relatively narrow premium customer base, analysts said it would likely need to offer more competitive pricing or eventually introduce a lower-cost model better suited to Vietnamese purchasing power.

Tesla Faces A Different Southeast Asian Market

Vietnam also presents a different competitive environment from Thailand and Indonesia. Thailand has a large established automotive manufacturing industry and has attracted numerous Chinese EV manufacturers. Indonesia’s EV strategy has been closely linked to its battery-material resources and incentives designed to encourage local production.

Vietnam already has what Tsoai described as “a national champion and a fast-expanding mobility ecosystem.” That means Tesla is entering a market where the infrastructure and consumer demand are developing together, but where a local competitor controls much of the ecosystem.

Sawangwong said Tesla and VinFast would initially be “mutual benchmarks rather than direct competitors,” reflecting the likelihood that the two companies could initially target somewhat different customer segments.

Tesla’s image could help it establish a foothold among Vietnamese consumers who associate the brand with technology and innovation. But that brand advantage will have to translate into a convincing ownership proposition.

Tesla would need to address charging availability, servicing, spare parts, pricing, and local distribution, areas where VinFast already has considerable infrastructure. That puts a big question on the company’s ability to turn a premium presence into meaningful market share.

Vietnam’s rapid EV adoption means Tesla does not need to persuade consumers that electric cars are viable. Instead, it must persuade them that a Tesla is worth choosing over a capable domestic alternative that has the advantage of local scale and an integrated charging and service network.

For now, Tesla’s registration of a Vietnamese entity is an early step rather than evidence of a full commercial launch. No timetable for sales or broader operations has been disclosed. But if Tesla proceeds, Vietnam could become an important test of whether its global brand and technology can overcome the advantages of a strong local EV ecosystem.

Meta’s new AI agent Muse is being marketed as something more consequential than a chatbot: a digital assistant that can act on behalf of consumers and potentially save them hundreds or even thousands of dollars.

Alexandr Wang, Meta’s chief AI officer, has been promoting the agent on X through the #MuseMoneyChallenge, encouraging users to share examples of money they say Muse has recovered or saved since its September 8 launch.

The pitch is straightforward. Instead of merely telling users how to reduce their expenses, Muse is designed to carry out some of the work itself. The agent can review finances, identify unnecessary spending, search for discounts, cancel subscriptions, and negotiate with companies for better deals.

The features are considered necessary for Meta’s broader AI strategy. Chatbots such as ChatGPT and Claude generally require users to initiate and oversee tasks. Agentic systems are being developed to take the next step by interacting with websites, businesses, and digital services with less human intervention.

Some early users say the results have been substantial.

Startup founder Joseph Devoy said Muse helped him find car insurance that was $3,500 cheaper per year than his previous plan. Another user said the agent identified a forgotten book subscription, canceled it, and obtained a refund covering a year’s worth of payments.

A Coinbase product manager, Nick Prince, said Muse helped him save $1,250 at a car dealership by helping him avoid upsells and a large fee. Another user said the agent discovered an unused $200 Verizon gift card.

Meta employees have also posted examples. One said Muse had saved him $2,120.95 through a combination of negotiating an AT&T bill, identifying Amazon returns, returning an IKEA piece of furniture and filing a veterinary claim.

The examples are striking, but they should not yet be treated as evidence that the typical Muse user will save $1,000. Many of the most prominent examples circulating online come from people participating in Wang’s social-media challenge, and several are from Meta employees. The reported savings also vary considerably in nature, from recurring bill reductions to refunds and benefits that users may have been able to obtain themselves.

Still, the marketing strategy reveals what Meta believes could make consumer AI agents different from conventional assistants. The value proposition is not simply that an AI system can answer questions faster. It is that the system can find money, complete administrative tasks, and produce a tangible financial return for the user.

That could bolster Meta’s position as the AI industry looks for ways to turn increasingly capable models into consumer products with recurring economic value.

Muse has already attracted significant attention. The app reached No. 1 among downloaded apps on Apple’s App Store and Google Play in the U.S., ahead of TikTok and ChatGPT, according to the report.

Meta’s potential distribution advantage is also difficult to ignore. The company says its services, including Facebook, Instagram and WhatsApp, reach nearly 3.9 billion users. If agentic AI becomes a mainstream consumer category, Meta has an unusually large existing audience to which it can introduce the technology.

But the same autonomy that makes agents potentially more useful also creates a new layer of conflict with businesses. Amazon, for example, blocked Muse from placing orders in shopping carts on its website on Monday, saying that use of the program to make purchases violated its terms of service.

That response points to a larger issue for agentic AI. A conventional chatbot largely operates within the interaction between a user and an AI system. An autonomous agent operates across the wider internet, interacting with companies whose websites, pricing systems, and customer-service processes were not necessarily designed to accommodate AI acting on behalf of consumers.

That creates competing incentives. Consumers may want an agent to cancel a subscription, negotiate a bill, find a discount, or complete a purchase without requiring their involvement. Businesses may have different views about automated negotiations, bulk interactions, or AI-generated transactions.

The resulting friction could become one of the defining issues for consumer agents.

Muse is also entering a market that is rapidly becoming crowded. Other agentic products are attempting to handle tasks such as booking travel, ordering products, and scheduling appointments. Instinct, for example, has attracted attention in Silicon Valley for carrying out a range of real-world tasks with relatively little user intervention.

The technology therefore faces a question that goes beyond whether AI can perform individual tasks. The major test lies on consumers eagerness to trust autonomous systems enough to give them access to sensitive financial information, accounts, subscriptions and purchasing decisions.

There is also a question of accountability. If an agent negotiates a bill incorrectly, cancels the wrong service, makes an unwanted purchase, or fails to obtain a promised refund, responsibility becomes more complicated than it is with a conventional search or chatbot interaction.

For Meta, those risks come alongside a potentially valuable new business model. An agent that can demonstrate measurable savings gives the company a stronger consumer proposition than an AI product whose benefits are difficult to quantify.

The early #MuseMoneyChallenge posts offer a glimpse of that proposition, but they are still anecdotal. The more important test will be whether Muse can deliver consistent savings for ordinary users, across a broad range of household expenses, without creating new problems in the process.

If it can, the economics of consumer AI could begin shifting from generating answers to taking actions. That would make the competition around agents less about which chatbot produces the best response and more about which system can reliably complete useful tasks in the real world.

Muse is currently testing that proposition at the boundary between consumers and the businesses they deal with. The savings claims are attracting users. Amazon’s resistance shows that the companies on the other side of those transactions are already paying attention.